Berenberg Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)

Berenberg Bank analyst Harry Gillis maintained a Buy rating on BioNTech SE yesterday and set a price target of $155.00. The company’s shares closed yesterday at $118.47.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Gillis is a 3-star analyst with an average return of 7.0% and a 59.26% success rate. Gillis covers the Healthcare sector, focusing on stocks such as Moderna, BioNTech SE, and Swedish Orphan Biovitrum AB.

In addition to Berenberg Bank, BioNTech SE also received a Buy from Goldman Sachs’s Asad Haider in a report issued on January 16. However, yesterday, TipRanks – OpenAI reiterated a Hold rating on BioNTech SE (NASDAQ: BNTX).

Based on BioNTech SE’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.52 billion and a GAAP net loss of $28.7 million. In comparison, last year the company earned a revenue of $1.24 billion and had a net profit of $198.1 million

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.